# Judged Worse Than Not Losing Weight

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-20 | Updated: 2026-10-27

Canonical page: https://glpwatchdog.org/research/judged-worse-than-not-losing-weight

> Researchers gave 607 people identical descriptions of a stranger, varying only how they had lost weight. The version who used a GLP-1 was judged more harshly than the version who had not lost weight at all.

## Key points

- The GLP-1 target was rated worse than the target who had NOT lost weight.
- After regain, the extra penalty for the drug vanished: GLP-1 and diet targets were judged alike, and both worse than someone who kept the weight off.
- So the extra stigma attaches to currently having lost weight BY MEDICATION.
- Vignette experiments: participants rated a fictional description, not a person.
- The striking comparison had a CI of 0.02–0.51, barely excluding zero.

Researchers gave 607 people a short description of a stranger and asked what they thought of them. The descriptions were identical except for one detail: how the person had lost weight. The version who had used a GLP-1 was judged more harshly than the version who had dieted, and **more harshly than the version who had not lost weight at all**.[1]

## What was done

The paper reports two randomized experiments. In each, participants read a brief history of a fictional person and then completed measures of weight-related stereotyping and willingness to associate with them. What varied between groups was only the weight history.

*Study 1: how the target was described, and how willing participants were to associate with them (N = 607; mean differences on a 1–7 scale).[1]*

| The person was described as… | Result |
| --- | --- |
| Having lost weight using a GLP-1 | **Rated most negatively** |
| Having lost weight via diet and exercise | Rated better than the GLP-1 target (mean difference 0.52, 95% CI 0.27–0.76) |
| **Not having lost weight** | **Also rated better than the GLP-1 target** (0.26, 95% CI 0.02–0.51) |

> People were less willing to associate with the person who lost weight on a GLP-1 than with the person who had not lost weight at all.

That last row is the finding. Weight stigma is well documented, and the expectation would be that losing weight reduces it. Here, losing it by this particular route left the person judged worse than if they had not lost it at all.

## The second experiment locates it precisely

A second experiment with 706 participants added the situation people fear: regain. Targets were described as having regained weight after stopping a GLP-1, having regained after stopping a diet and exercise plan, never having lost weight, or having maintained a loss.

- **After regain, the GLP-1 and diet-and-exercise targets were judged the same.** The extra penalty for the drug disappeared.
- **Both were judged worse than the person who maintained their loss** (both P ≤ 0.001).

> **Put the two studies together and the stigma has a precise shape.** The extra penalty does not attach to having taken a drug, because it vanishes once weight returns and both regain groups are judged alike. Regain carries a penalty of its own, the same whichever way the weight was lost. The extra penalty attaches to *currently being someone who lost weight with medication*, and it is heavier than the stigma of not having lost weight at all.

That is a sharper result than “people are judgmental about these drugs,” and it fits what patients report. Our interview-based coverage found stigma emerging as one of eight themes, varying by what the drug had been prescribed for (see [eight things patients said](https://glpwatchdog.org/research/eight-things-patients-said)). This is the experimental counterpart, and it puts a direction and a size on something people described from the inside.

## What a vignette study can and cannot show

> **Nobody in these experiments met anyone.** Participants read a paragraph about a person who does not exist and rated a description. That measures stated attitudes under conditions designed to isolate one variable, which is why the design can prove that the *route* to weight loss changes judgments. It is not evidence about how people behave toward actual colleagues, friends or patients.

Stated attitudes and behavior can come apart, so do not read this as a measurement of what you will encounter.

The intervals matter too. Both gaps are in willingness to associate with the person. The gap against the diet-and-exercise target was 0.52 with an interval from 0.27 to 0.76, which is solid. The gap against the *no weight loss* target, which is the striking one, was 0.26 with an interval from 0.02 to 0.51. That barely excludes zero, on a scale that runs from 1 to 7. It is the most interesting finding here and the least firmly established.

## Why it is worth knowing anyway

It names something people are told they are imagining. A patient who senses that disclosing this medication costs them something is not being oversensitive. There is experimental evidence that the disclosure changes how they are evaluated, in the direction they suspect.

It also bears on a practical decision that comes up constantly: whether to tell anyone. There are good clinical reasons to disclose. A medication missing from your record is invisible to interaction checking and to the team preparing a procedure, which we set out in [what your doctor cannot see](https://glpwatchdog.org/research/what-your-doctor-cannot-see). Those reasons do not disappear because disclosure carries a social cost, and pretending the cost is not there helps nobody.

The authors’ own conclusion is that stigma follows people across the whole cycle of losing and regaining, and that stigma-reduction efforts belong in weight management. That is a reasonable thing to conclude from two experiments with fictional targets, stated at about the right strength.

## Frequently asked questions

### Are people judged for using a GLP-1 to lose weight?

In a randomized vignette experiment with 607 participants, a person described as having lost weight with a GLP-1 was evaluated more negatively than one described as having lost weight through diet and exercise, and more negatively than one described as not having lost weight at all.

### Does the judgment persist after regaining weight?

The extra penalty disappeared. In a second experiment, targets who regained after stopping a GLP-1 and those who regained after stopping a diet plan were judged the same, and both worse than someone who maintained a loss.

### What exactly is being stigmatized then?

The extra penalty attaches to currently being someone who lost weight with medication. It is not the drug itself, since that penalty vanishes on regain. Regain carries a penalty of its own, but the same one for both regain groups, who were judged alike and both worse than someone who maintained a loss.

### How much should this be trusted?

It shows that the described route to weight loss changes how a description is rated, which the design proves cleanly. It is not evidence about how people behave toward real individuals, and the most striking comparison had a confidence interval that barely excluded zero.

### Should someone hide that they take one?

That is a personal decision, and the clinical reasons to disclose are strong. A medication absent from your record is invisible to interaction checking and to anyone preparing you for a procedure. The social cost appears to be real, and it does not remove the clinical reasons.

## References

1. Standen EC, Phelan SM, Tomiyama AJ. An experimental investigation of the stigmatization of weight loss and regain from GLP-1 receptor agonist use and cessation. International Journal of Obesity. 2026. PMID: 41933207. https://pubmed.ncbi.nlm.nih.gov/41933207/

---

Cite as: GLP Watchdog, Nora Bissett, "Judged Worse Than Not Losing Weight", published 2026-08-20, updated 2026-10-27. https://glpwatchdog.org/research/judged-worse-than-not-losing-weight

Canonical HTML page: https://glpwatchdog.org/research/judged-worse-than-not-losing-weight

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
